Table 2. Univariate analysis of clinicopathologic characteristic related with overall survival.
| Variable | Patients N(%) | Event | Median survival(months) | P value |
|---|---|---|---|---|
| Age(years) | ||||
| <50 | 28(26.4) | 17 | 19 | 0.2238 |
| >50 | 78(73.6) | 50 | 12 | |
| Gender | ||||
| Female | 37(34.9) | 24 | 12 | 0.8384 |
| Male | 69(65.1) | 43 | 13 | |
| Performance Status(ECOG) | ||||
| 0 | 13(12.3) | 6 | 78 | 0.0014 |
| 1 | 86(81.1) | 57 | 12 | |
| 2 | 4(3.8) | 2 | 2 | |
| 3 | 1(0.9) | 0 | 0 | |
| 4 | 2(1.9) | 2 | 1 | |
| Histology | ||||
| Poorly differentiated carcinoma | 26(24.5) | 15 | 18 | 0.0016 |
| Adenocarcinoma | 43(40.6) | 32 | 4 | |
| Squamous cell carcinoma | 28(26.4) | 15 | 24 | |
| Undifferentiated carcinoma | 9(8.5) | 5 | 119 | |
| Lactate dehydrogenase(IU/L) | ||||
| Normal | 14(13.2) | 4 | 6 | 0.0002 |
| High | 36(34.0) | 27 | 0 | |
| Not assessed | 56(52.8) | |||
| CK7 immunosttinng | ||||
| Negative | 27(25.5) | 17 | 24 | 0.1111 |
| Positive | 60(56.6) | 42 | 9 | |
| Not assessed | 19(17.9) | |||
| CK20 Immunostaining | ||||
| Negative | 77(72.6) | 50 | 14 | 0.002 |
| Positive | 10(9.4) | 9 | 1 | |
| Not assessed | 19(17.9) | |||
| CDX2 Immunostaining | ||||
| Negative | 76(71.7) | 51 | 14 | 0.0418 |
| Positive | 11(10.4) | 8 | 1 | |
| Not assessed | 19(17.9) | |||
| Lung Metastasis | ||||
| Absent | 89(84.0) | 55 | 2 | 0.2142 |
| Present | 17(16.0) | 12 | 0 | |
| Liver Metastasis | ||||
| Absent | 96(90.6) | 60 | 13 | 0.4388 |
| Present | 10(9.4) | 7 | 7 | |
| Bone Metastasis | ||||
| Absent | 78(73.6) | 47 | 15 | 0.0171 |
| Present | 28(26.4) | 20 | 5 | |
| Brain Metastasis | ||||
| Absent | 70(66.0) | 38 | 16 | 0.6027 |
| Present | 8(7.5) | 8 | 24 | |
| Symptomatically suspicous | 2(1.9) | |||
| Not evaluated | 26(24.5) | |||
| Treatment | ||||
| No treatment | 19(17.9) | 10 | 2 | 0.0000 |
| Operation | 40(37.7) | 11 | 6 | |
| Chemotherapy | 41(38.7) | 13 | 13 | |
| Radiation therapy | 44(41.5) | 15 | 7 | |
| Concurrent chemoradiation | 16(15.1) | 18 | 34 | |
| CEA | ||||
| Normal | 48(45.3) | 30 | 14 | 0.0468 |
| High | 32(30.2) | 23 | 4 | |
| Not assessed | 26(24.5) | 0 | ||
| CA19-9 | ||||
| Normal | 45(42.5) | 25 | 15 | 0.0031 |
| High | 26(24.5) | 21 | 2 | |
| Not assessed | 35(33.0) | 0 | ||
| CA125 | ||||
| Normal | 16(15.1) | 13 | 12 | 0.7652 |
| High | 24(22.6) | 18 | 4 | |
| Not assessed | 66(62.3) | 0 | ||
| CA15-3 | ||||
| Normal | 20(18.9) | 13 | 13 | 0.5559 |
| High | 6(5.6) | 5 | 4 | |
| Not assessed | 80(75.5) | 0 | ||
| AFP | 0 | |||
| Normal | 48(45.3) | 31 | 14 | 0.1506 |
| High | 3(2.8) | 2 | 0 | |
| Not assessed | 55(51.9) | 0 | ||
| PIVKA-II | ||||
| Normal | 18(17.0) | 14 | 6 | 0.6332 |
| Increased | 12(11.3) | 9 | 3 | |
| Not assessed | 76(71.7) | |||
| SCCAg | ||||
| Normal | 20(18.9) | 14 | 14 | 0.6109 |
| Increased | 8(7.5) | 6 | 9 | |
| Not assessed | 78(73.6) | |||
| Prognostic group | 0 | |||
| Favorable | 31(29.2) | 19 | 20 | 0.191 |
| Non-favorable | 75(70.8) | 48 | 11 | |
| Prognostic group (by Culine) | ||||
| Good risk | 64(60.4) | 36 | 19 | 0.0005 |
| Poor risk | 42(39.6) | 31 | 7 | |
| Metastasis confined to lymph node | ||||
| Yes | 36(34.0) | 16 | 9 | 0.0015 |
| No | 70(66.0) | 51 | 78 | |
| Lower GI profile | ||||
| Lower GI profile | 6(5.7) | 5 | 13 | 0.126 |
| Non-Lower GI profile | 81(76.4) | 54 | 1 | |
| Not assessed | 19(17.9) |